Current Issue

Review looks at metformin safety, effectiveness in patients with reduced renal function

Metformin appears to be associated with reduced mortality at estimated glomerular filtration rates as low as 45 mL/min/1.73 m2, but safety concerns arise with rates at or below 30 mL/min/1.73 m2.

Depression associated with death in older patients with type 2 diabetes

A study that screened patients with type 2 diabetes in Spain for depression found that depression was associated with higher all-cause mortality in patients older than age 65 years, but not in younger patients.

Association between diabetes and worse COVID-19 outcomes more marked in younger adults

Among patients hospitalized with COVID-19, diabetes was a more significant risk factor for death, intensive care, or intubation in those younger than 50 years compared to older patients, a retrospective French study found.

MKSAP quiz: Elevated liver chemistries

This month's quiz asks readers to evaluate a 35-year-old woman with type 2 diabetes mellitus, hypertension, hyperlipidemia, obesity, and the metabolic syndrome.

Spotlight on CVD risk prediction

One study found that wider diabetes screening made a cardiovascular disease (CVD) prediction tool less accurate, while other research evaluated the ability of coronary artery calcium testing and a neuropathy questionnaire to identify type 2 diabetes patients with high CVD risk.

CGM decreased HbA1c levels, hypoglycemia in patients with type 2 diabetes

Two industry-supported studies of continuous glucose monitoring (CGM) found encouraging results in patients with type 2 diabetes, leading editorialists to call for broadened access to the technology in this population, particularly in primary care.

New recommendations advise on adding SGLT-2 inhibitors and GLP-1 receptor agonists

A new guideline from The BMJ strongly recommends sodium-glucose cotransporter-2 (SGLT-2) inhibitors for patients with diabetes and established cardiovascular and chronic kidney disease, in addition to offering weaker support for starting glucagon-like peptide-1 (GLP-1) receptor agonists in this same patient population.

In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs

A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.

In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y

Previous research has shown short-term remission of type 2 diabetes after bariatric surgery, but a decade of data from this randomized trial should reassure patients of the favorable long-term benefits and safety of this intervention, an ACP Journal Club commentary said.

SGLT-2 revisited: Diabetes management in chronic kidney disease

The latest episode of Annals On Call features host Robert M. Centor, MD, MACP, and two guests discussing management of patients who have both diabetes and chronic kidney disease.

Semaglutide injection approved for chronic weight management

First approved to treat type 2 diabetes in 2017, the drug has a new indication for chronic weight management in adults with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related condition, such as type 2 diabetes, and those with a BMI of 30 kg/m2 or greater.